Table 4.
Fatty acids | HbSS (untreated) | HbSS (treated) | HbAA (healthy control) |
---|---|---|---|
16:0 | 21.1 ± 4.3* | 25.3 ± 3.5 | 26.1 ± 2.2++ |
18:0 | 8.7 ± 2.2* | 11.9 ± 3.5 | 11.3 ± 2.0++ |
20:0 | 2.0 ± 0.2 | 1.00 ± 0.2××× | 1.44 ± 0.2+++ |
22:0 | 8.1 ± 1.5* | 6.6 ± 1.3 | 7.6 ± 1.1 |
24:0 | 25.3 ± 4.8*** | 18.5 ± 2.9×× | 21.6 ± 2.6+ |
∑saturates | 63.9 ± 3.8 | 63.8 ± 3.1××× | 68.2 ± 1.4++ |
| |||
16:1n-7 | tr. | tr. | tr. |
18:1n-7 | 0.3 ± 0.1*** | 0.7 ± 0.1×× | 0.5 ± 0.1+++ |
18:1n-9 | 3.8 ± 1.9 | 3.4 ± 0.6××× | 2.0 ± 0.3++ |
24:1n-9 | 17.8 ± 3.6** | 14.2 ± 1.7 | 13.9 ± 1.7++ |
∑monoenes | 21.9 ± 2.8*** | 18.3 ± 2.0× | 16.5 ± 1.8+++ |
| |||
18:2n-6 | 2.1 ± 1.1 | 2.3 ± 0.6 | 2.0 ± 0.3 |
18:3n-6 | tr. | tr. | tr. |
20:2n-6 | 0.4 ± 0.3** | 0.1 ± 0.04×× | 0.09 ± 0.04++ |
20:3n-6 | 0.3 ± 0.1** | 0.5 ± 0.1×× | 0.3 ± 0.1 |
20:4n-6 | 3.7 ± 1.3* | 4.9 ± 1 | 5.1 ± 1.3++ |
22:4n-6 | 1.8 ± 1.0 | 2.0 ± 0.8× | 1.3 ± 0.4 |
22:5n-6 | 1.4 ± 0.6 | 1.3 ± 0.6 | 1.1 ± 0.3 |
∑metabolites | 7.5 ± 2.9 | 8.4 ± 1.9 | 7.9 ± 2.1 |
∑n-6 | 9.6 ± 3.5 | 10.8 ± 1.7 | 9.9 ± 2.2 |
| |||
18:3n-3 | tr. | tr. | tr. |
20:5n-3 | 0.11 ± 0.02*** | 0.07 ± 0.02 | 0.06 ± 0.02+++ |
22:5n-3 | 0.4 ± 0.2 | 0.45 ± 0.2 | 0.4 ± 0.1 |
22:6n-3 | 1.4 ± 0.7 | 1.8 ± 0.8 | 1.7 ± 0.6 |
∑metabolites | 1.9 ± 0.8 | 2.4 ± 0.9 | 2.1 ± 0.7 |
∑n-3 | 1.9 ± 0.8 | 2.4 ± 0.9 | 2.1 ± 0.7 |
| |||
N6/N3 | 5.3 ± 1.6 | 5.3 ± 1.7 | 4.9 ± 1.1 |
tr.: trace.
HU-untreated versus treated HbSS patients: *P < 0.05, **P < 0.01, ***P < 0.001.
HU-untreated HbSS patients versus HbAA healthy controls: + P < 0.05, ++ P < 0.01, +++ P < 0.001.
HU-treated HbSS patients versus HbAA healthy controls: × P < 0.05, ×× P < 0.01, ××× P < 0.001.